Whole genome sequencing of escherichia coli and salmonella enterica isolates screened from companion and food animals with potential public and animal health importance

Active Cooperative Agreement Awarded

Award ID
U18FD008900
Recipient
Awarding agency
Obligated
$151,750

Award facts

Assistance listing
93.103 Food and Drug Administration Research
Completion date 18% complete
Funding agency
Center for Veterinary Medicine Food and Drug Administration, Department of Health and Human Services
Place of performance
Manhattan, KS 66506, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services Food and Drug Administration, through its Center for Veterinary Medicine, awarded Kansas State University a Cooperative Agreement (U18FD008900) with $151,750 obligated on September 23, 2026, under Assistance Listing 93.103, Food and Drug Administration Research. The recipient will perform whole genome sequencing on 100 Escherichia coli and 100 Salmonella enterica isolates selected from its archived collection and screened from companion and food animals, with a target of 90 high-quality draft and complete genomes per bacterial species. Assembly uses Illumina's DRAGEN Small Whole Genome Sequencing pipeline for primer trimming, quality control, and initial contig, scaffold, and genome assembly. The project also adds eae and espV markers to an existing ETEC molecular assay to screen E. coli isolates for EPEC, and it prioritizes Salmonella isolates from serotypes carrying multiple drug resistance genes, using serotype and antimicrobial resistance profiles already identified for most isolates. Performance runs from the September 23, 2026 award date through an ultimate completion date of August 31, 2027, at Manhattan, Kansas 66506.

Description

Abstract
Both escherichia coli and salmonella enterica are major foodborne pathogens that pose a threat to human and animal health (magossi ET AL., 2019; pereira ET AL., 2025; scallan ET AL., 2011). Shiga toxin-producing E. Coli (STEC), enterotoxigenic E. Coli (ETEC) and enteropathogenic E. Coli (EPEC) are the three main E. Coli pathotypes responsible for most human enteric infections (gilligan, 1999). Salmonella serotypes most frequently associated with outbreaks in recent years are reported as: enteritidis (no.=65), typhimurium (24), I,4,[5],12:I:- (19), heidelberg (17), newport (13), infantis (9), braenderup (8), thompson (5), javiana (5) and uganda (5) (katz ET AL., 2024). We have previously developed molecular assays for detection of STEC (BAI ET AL., 2012) and ETEC (kvdl SOP), and both can be used for E. Coli isolate screening. Because EAE (encoding intimin) and espv (ttss effector gene) are typical markers for EPEC, these two genes will be added into the ETEC assay for EPEC isolate screening. Serotype and antimicrobial resistance (AMR) profiles are already identified for most salmonella isolates in our collection. Prioritizing serotypes with multiple drug resistance genes may allow selection of isolates with greater relevance to human health. One hundred E. Coli and one hundred salmonella isolates will be selected from our archived collection, and subjected to whole genome sequencing. Instead of investing resources in extensive RE-sequencing of isolates that poorly sequenced in the first round, we propose to generate 90 high-quality draft and complete genomes for each bacterial species. Illumina's dragen small whole genome sequencing pipeline will be used for primer trimming, quality control and initial contig, scaffold and genome assembly. Raw sequencing data will be separated based on bar codes assigned to each isolate. Assembled contigs, scaffolds and genomes will be RE-evaluated using qiagen CLC genomics workbench and/or an in-house developed bioinformatics pipeline that is installed on a VET-lirn supported computer server. All assembled draft and complete genomes will be assessed for accuracy and completeness. The highest quality draft and complete genomes for each species will be submitted to genbank using ncbi batch WGS submission channel under species-specific bioprojects established prior to submission. Following any brief holding period required for manuscript drafting, all genome sequences will be made publicly accessible.

Quick answers

Who received award U18FD008900?

U18FD008900 was awarded to Kansas State University by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 23, 2026.

How much is award U18FD008900 worth?

$151,750 has been obligated on U18FD008900.

Which agency awarded U18FD008900?

FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded U18FD008900, with funding from Center for Veterinary Medicine (Food and Drug Administration).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award